全文获取类型
收费全文 | 941篇 |
免费 | 108篇 |
国内免费 | 11篇 |
专业分类
耳鼻咽喉 | 3篇 |
儿科学 | 32篇 |
妇产科学 | 10篇 |
基础医学 | 249篇 |
临床医学 | 79篇 |
内科学 | 335篇 |
皮肤病学 | 11篇 |
神经病学 | 72篇 |
特种医学 | 70篇 |
外科学 | 87篇 |
综合类 | 1篇 |
预防医学 | 21篇 |
眼科学 | 6篇 |
药学 | 40篇 |
中国医学 | 1篇 |
肿瘤学 | 43篇 |
出版年
2024年 | 4篇 |
2023年 | 7篇 |
2022年 | 11篇 |
2021年 | 18篇 |
2020年 | 21篇 |
2019年 | 34篇 |
2018年 | 29篇 |
2017年 | 19篇 |
2016年 | 28篇 |
2015年 | 34篇 |
2014年 | 33篇 |
2013年 | 40篇 |
2012年 | 69篇 |
2011年 | 82篇 |
2010年 | 36篇 |
2009年 | 36篇 |
2008年 | 50篇 |
2007年 | 63篇 |
2006年 | 58篇 |
2005年 | 44篇 |
2004年 | 52篇 |
2003年 | 42篇 |
2002年 | 42篇 |
2001年 | 24篇 |
2000年 | 20篇 |
1999年 | 17篇 |
1998年 | 19篇 |
1997年 | 12篇 |
1996年 | 14篇 |
1995年 | 16篇 |
1994年 | 11篇 |
1993年 | 9篇 |
1992年 | 9篇 |
1991年 | 7篇 |
1990年 | 8篇 |
1989年 | 3篇 |
1988年 | 5篇 |
1987年 | 5篇 |
1986年 | 3篇 |
1985年 | 2篇 |
1984年 | 2篇 |
1978年 | 2篇 |
1976年 | 3篇 |
1974年 | 2篇 |
1972年 | 1篇 |
1971年 | 2篇 |
1970年 | 1篇 |
1969年 | 2篇 |
1967年 | 1篇 |
1965年 | 1篇 |
排序方式: 共有1060条查询结果,搜索用时 0 毫秒
11.
Tubular ectasia of the rete testis (TERT) is a benign entity due to dilation of the tubules of the rete testis. Most of the
time it is discovered incidentally on scrotal sonograms and may be misinterpreted as malignant. This article outlines the
diagnostic criteria of TERT, its possible causes, its incidence and its potential evolution. Recognizing this entity owing
to its characteristic clinical, sonographic and, if necessary, MRI features is important to avoid unnecessary surgery or biopsies.
Received: 4 August 1998; Revised: 15 April 1999; Accepted: 19 April 1999 相似文献
12.
D. De Craemer M. J. Zweens S. Lyonnet R. J. A. Wanders B. T. Poll-The R. B. H. Schutgens J. J. J. Waelkens J. M. Saudubray F. Roels 《Virchows Archiv : an international journal of pathology》1991,419(6):523-525
Summary We report very large hepatic peroxisomes (d-circle >1 m) in a patient with rhizomelic chondrodysplasia punctata and a patient with acyl-CoA oxidase deficiency. The effects of peroxisomal enlargement on the enzymatic activity are discussed. As increase in peroxisomal size is also reported in at least 12 other patients with peroxisomal disorders, we propose, a relationship between the enlargement of the organelles and their functional deficiency. 相似文献
13.
Transrectal high-intensity focused ultrasound: minimally invasive therapy of localized prostate cancer 总被引:3,自引:0,他引:3
Gelet A Chapelon JY Bouvier R Rouvière O Lasne Y Lyonnet D Dubernard JM 《Journal of endourology / Endourological Society》2000,14(6):519-528
BACKGROUND AND PURPOSE: Criteria for determining the durability of the response to transrectal high-intensity focused ultrasound (HIFU) ablation of prostate cancer have been established by calculating progression-free probability. PATIENTS AND METHODS: A series of 82 patients (mean age 71 +/- 5.7 years) with biopsy-proven localized (stage T1-T2) cancer who were not suitable candidates for radical surgery underwent transfectal HIFU ablation with the Ablatherm machine. The mean follow-up was 17.6 months (range 3-68 months). The mean serum prostate specific antigen (PSA) value and mean prostate volume were 8.11 +/- 4.64 ng/mL and 34.9 +/- 17.4 cm3, respectively. Progression was rigidly defined as any positive biopsy result, regardless of PSA concentration, or three successive PSA increases for patients with a negative biopsy (PSA velocity > or = 0.75). Times to specific events (positive biopsy and PSA elevation) were analyzed with the Kaplan-Meier survival method. RESULTS: Overall, 62% of the patients exhibited no evidence of disease progression 60 months after transrectal HIFU ablation. In particular, the disease-free rate was 68% for the moderate-risk group of 50 patients (PSA < 15.0 ng/mL, Gleason sum < 8, prostate volume < 40 cm3, and number of positive biopsies < 5). For the low-risk group of 32 patients (PSA < 10 ng/mL and Gleason sum < 7), the disease-free survival rate was 83%. CONCLUSION: Transrectal HIFU prostate ablation is an effective therapeutic alternative for patients with localized prostatic adenocarcinoma. 相似文献
14.
15.
16.
Comparison of non-invasive liver fibrosis biomarkers in HIV/HCV co-infected patients: the fibrovic study--ANRS HC02 总被引:1,自引:0,他引:1
Cacoub P Carrat F Bédossa P Lambert J Pénaranda G Perronne C Pol S Halfon P 《Journal of hepatology》2008,48(5):765-773
BACKGROUND/AIMS: To compare non-invasive biological liver fibrosis scores, as alternatives to liver biopsy, in HIV/HCV co-infected patients. METHODS: Two hundred and seventy-two HIV/HCV patients, nai ve for HCV treatment, underwent liver biopsy [197 (72%) men, 39.9 years, fibrosis stage (Metavir) F1 (25%), F2 (40%), F3 (25%), F4 (10%), median CD4 486/mm(3) and median HIV viral load 3.5log. Fibrotest (FT), Hepascore (HS), Fibrometer (FM), SHASTA, APRI, Forns index, and Fib-4 were tested in order to differentiate patients with mild to moderate fibrosis (F2) and those with advanced fibrosis (F3). The AUROC and the rate of well-classified patients were compared to liver biopsy. RESULTS: FT, HS, and FM were able to stage liver fibrosis in all patients with AUROCs of 0.78, 0.84 and 0.89 for the diagnosis of F2, respectively. The correlation coefficient indexes were 0.37, 0.46 and 0.48, respectively. The rates of well-classified patients were 62%, 68% and 71%, respectively. Fib-4, APRI and the Forn's index were only able to stage 37-61% of patients and showed lower accuracies. Using a combination of FT, HS and FM did not significantly increase the performance of each test. CONCLUSIONS: In HIV/HCV co-infected patients, Fibrometer, Hepascore and Fibrotest outperformed other non-invasive liver fibrosis biomarkers for the prediction of significant liver fibrosis. 相似文献
17.
18.
19.
20.
Nsimba B Malonga DA Mouata AM Louya F Kiori J Malanda M Yocka D Oko-Ossho J Ebata-Mongo S Le Bras J 《The American journal of tropical medicine and hygiene》2004,70(2):133-138
Congo is facing frequent failures of treatment of Plasmodium falciparum malaria with chloroquine (CQ), which is still recommended and used as a first-line drug. In Pointe-Noire and Brazzaville, the two largest cities that contain approximately 60% of the population of Congo, we compared the efficacy of CQ versus sulfadoxine/pyrimethamine (SP) for treatment of uncomplicated malaria in children 6-59 months old (mean = 33 months) using the standard World Health Organization (WHO) 14-day in vivo test in two phases between 1999 and 2002. Patients enrolled were randomly assigned to receive SP (25 mg/kg of sulfadoxine and 1.25 mg/kg of pyrimethamine) or CQ (25 mg/kg). In the first phase of the study, 46 patients were assigned to the CQ (n = 23) or SP (n = 23) groups in Pointe-Noire and 52 children were assigned to the CQ (n = 26) or to SP (n = 26) groups in Brazzaville. Results were interpreted according to the WHO lot quality assurance sampling method, and treatment failure rates for SP versus CQ were < 25% versus > 25% in both cities. In the second phase of the study, we accurately determined the actual proportion of treatment failures for SP in Brazzaville. Thus, in 75 of the 80 children enrolled and followed-up until day 14, no clinical or parasitologic failure was recorded and no serious adverse reaction was observed. Since the CQ treatment failure rate exceeds the unacceptable upper limit, SP seems well to be an appropriate alternative for the first-line treatment of uncomplicated P. falciparum malaria, at least in the settings of the present study. 相似文献